<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39316018</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>221</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20240637</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20240637</ELocationID><Abstract><AbstractText>Tick-borne encephalitis (TBE) virus (TBEV) is transmitted to humans via tick bites. Infection is benign in &gt;90% of the cases but can cause mild (&lt;5%), moderate (&lt;4%), or severe (&lt;1%) encephalitis. We show here that ∼10% of patients hospitalized for severe TBE in cohorts from Austria, Czech Republic, and France carry auto-Abs neutralizing IFN-α2, -β, and/or -ω at the onset of disease, contrasting with only ∼1% of patients with moderate and mild TBE. These auto-Abs were found in two of eight patients who died and none of 13 with silent infection. The odds ratios (OR) for severe TBE in individuals with these auto-Abs relative to those without them in the general population were 4.9 (95% CI: 1.5-15.9, P &lt; 0.0001) for the neutralization of only 100 pg/ml IFN-α2 and/or -ω, and 20.8 (95% CI: 4.5-97.4, P &lt; 0.0001) for the neutralization of 10 ng/ml IFN-α2 and -ω. Auto-Abs neutralizing type I IFNs accounted for ∼10% of severe TBE cases in these three European cohorts.</AbstractText><CopyrightInformation>© 2024 Gervais et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gervais</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1083-5787</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Marchal</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0648-8126</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fortova</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-8701-7867</Identifier><AffiliationInfo><Affiliation>Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.</Affiliation><Identifier Source="ROR">https://ror.org/02j46qs45</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Parasitology, Biology Centre of the Czech Academy of Science , České Budějovice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Berankova</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0009-1630-5902</Identifier><AffiliationInfo><Affiliation>Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.</Affiliation><Identifier Source="ROR">https://ror.org/02j46qs45</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Parasitology, Biology Centre of the Czech Academy of Science , České Budějovice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krbkova</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9834-536X</Identifier><AffiliationInfo><Affiliation>Department of Children's Infectious Diseases, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.</Affiliation><Identifier Source="ROR">https://ror.org/02j46qs45</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pychova</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2691-169X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.</Affiliation><Identifier Source="ROR">https://ror.org/02j46qs45</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salat</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9915-8953</Identifier><AffiliationInfo><Affiliation>Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.</Affiliation><Identifier Source="ROR">https://ror.org/02j46qs45</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Parasitology, Biology Centre of the Czech Academy of Science , České Budějovice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shuxiang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9185-6813</Identifier><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerrouche</LastName><ForeName>Nacim</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0003-1922-9008</Identifier><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Voyer</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7253-3135</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiasny</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1902-8674</Identifier><AffiliationInfo><Affiliation>Medical University of Vienna, Center for Virology , Vienna, Austria.</Affiliation><Identifier Source="ROR">https://ror.org/05n3x4p02</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raffl</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0001-9125-3892</Identifier><AffiliationInfo><Affiliation>Medical University of Vienna, Center for Virology , Vienna, Austria.</Affiliation><Identifier Source="ROR">https://ror.org/05n3x4p02</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schieber Pachart</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-2947-3717</Identifier><AffiliationInfo><Affiliation>Clinical Research Department, Hôpitaux Civils de Colmar, Colmar, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fafi-Kremer</LastName><ForeName>Samira</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3886-7833</Identifier><AffiliationInfo><Affiliation>Institut de Virologie, Strasbourg University Hospital, Strasbourg University, INSERM Unité Mixte de Recherche (UMR) S1109 , Strasbourg, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravier</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4230-5534</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Department, Hôpitaux Civils, Colmar, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbiani</LastName><ForeName>Davide F</ForeName><Initials>DF</Initials><Identifier Source="ORCID">0000-0001-7379-3484</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.</Affiliation><Identifier Source="ROR">https://ror.org/01z1gye03</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7016-6493</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Margaret R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-5177-2068</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0003-3087-8079</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissmann</LastName><ForeName>Gaia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9157-2340</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics and Neonatology, F. Tappeiner Hospital, Merano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamal Eldin</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0006-4025-2773</Identifier><AffiliationInfo><Affiliation>Infectious Disease Unit, Provincial Hospital of Bolzano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robatscher</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0003-1913-5642</Identifier><AffiliationInfo><Affiliation>Laboratory of Microbiology and Virology, SABES-ASDAA, Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erne</LastName><ForeName>Elke Maria</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-9295-7998</Identifier><AffiliationInfo><Affiliation>Infectious Disease Unit, Provincial Hospital of Bolzano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagani</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4008-6756</Identifier><AffiliationInfo><Affiliation>Laboratory of Microbiology and Virology, SABES-ASDAA, Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Borghesi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8773-9144</Identifier><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, San Matteo Research Hospital, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Swiss Federal Institute of Technology , Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Puel</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2603-0323</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bastard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5926-8437</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Velay</LastName><ForeName>Aurélie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9174-8959</Identifier><AffiliationInfo><Affiliation>Institut de Virologie, Strasbourg University Hospital, Strasbourg University, INSERM Unité Mixte de Recherche (UMR) S1109 , Strasbourg, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Martinot</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4524-9064</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Department, Hôpitaux Civils, Colmar, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hansmann</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8903-0027</Identifier><AffiliationInfo><Affiliation>CHU de Strasbourg, Service des Maladies Infectieuses et Tropicales , Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Aberle</LastName><ForeName>Judith H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-1197-3935</Identifier><AffiliationInfo><Affiliation>Medical University of Vienna, Center for Virology , Vienna, Austria.</Affiliation><Identifier Source="ROR">https://ror.org/05n3x4p02</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ruzek</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4655-2380</Identifier><AffiliationInfo><Affiliation>Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.</Affiliation><Identifier Source="ROR">https://ror.org/02j46qs45</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Parasitology, Biology Centre of the Czech Academy of Science , České Budějovice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cobat</LastName><ForeName>Aurélie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7209-6257</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Shen-Ying</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-9449-3672</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Casanova</LastName><ForeName>Jean-Laurent</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-7782-4169</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation><Identifier Source="ROR">https://ror.org/02vjkv261</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Imagine Institute, Paris Cité University , Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA.</Affiliation><Identifier Source="ROR">https://ror.org/0420db125</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute , New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Strasbourg University</Agency><Country /></Grant><Grant><GrantID>EQU201903007798</GrantID><Agency>French Foundation for Medical Research</Agency><Country /></Grant><Grant><Agency>Rockefeller University</Agency><Country /></Grant><Grant><Agency>Meyer Foundation</Agency><Country /></Grant><Grant><Agency>European Union</Agency><Country /></Grant><Grant><GrantID>RC08061819</GrantID><Agency>Italian Ministry of Health</Agency><Country /></Grant><Grant><GrantID>ANR-10-IAHU-01</GrantID><Agency>Agence Nationale de la Recherche</Agency><Country /></Grant><Grant><GrantID>08061821</GrantID><Agency>San Matteo Hospital</Agency><Country /></Grant><Grant><Agency>Imagine Institute</Agency><Country /></Grant><Grant><GrantID>R01 AI163029</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LX22N-PO5103</GrantID><Agency>National Institute of Virology and Bacteriology</Agency><Country /></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI124690</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Battersea &amp; Bowery Advisory Group</Agency><Country /></Grant><Grant><GrantID>R01AI163029</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Grandir - Fonds de solidarité pour l'enfance</Agency><Country /></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><Agency>Square Foundation</Agency><Country /></Grant><Grant><GrantID>PRI 7782</GrantID><Agency>Strasbourg University Hospital</Agency><Country /></Grant><Grant><GrantID>NU22-05-00659</GrantID><Agency>Czech Ministry of Health</Agency><Country /></Grant><Grant><Agency>Fondation du Souffle</Agency><Country /></Grant><Grant><Agency>SCOR Corporate Foundation for Science</Agency><Country /></Grant><Grant><Agency>St. Giles Foundation</Agency><Country /></Grant><Grant><GrantID>UMR_S 1109</GrantID><Agency>Institut National de la Santé et de la Recherche Médicale</Agency><Country /></Grant><Grant><Agency>Bettencourt-Schueller Foundation</Agency><Country /></Grant><Grant><GrantID>PHRCN-17-0382</GrantID><Agency>Ministry of Health</Agency><Country /></Grant><Grant><Agency>Paris Cité University</Agency><Country /></Grant><Grant><Agency>JPB Foundation</Agency><Country /></Grant><Grant><GrantID>MESRI-COVID-19</GrantID><Agency>French Ministry of Higher Education, Research, and Innovation</Agency><Country /></Grant><Grant><Agency>Stavros Niarchos Foundation</Agency><Country /></Grant><Grant><Agency>Fisher Center for Alzheimer's Research Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004675" MajorTopicYN="Y">Encephalitis, Tick-Borne</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004669" MajorTopicYN="N">Encephalitis Viruses, Tick-Borne</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018153" MajorTopicYN="N" Type="Geographic">Czech Republic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: The Center for Virology, Medical University of Vienna, Austria, received an Investigator-Initiated Research grant from Pfizer (WI235042), with J.H. Aberle as principal investigator, which is not related to the submitted work. J.-L. Casanova reported a patent to PCT/US2021/042741 pending. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316018</ArticleId><ArticleId IdType="pmc">PMC11448868</ArticleId><ArticleId IdType="doi">10.1084/jem.20240637</ArticleId><ArticleId IdType="pii">276989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ackermann-Gäumann, R., Eyer C., Vock M., Gowland P., Tinguely C., Leib S.L., Bori M., Buser A., Fontana S., Thierbach J., et al. . 2023. Prevalence of anti-tick-borne encephalitis virus (TBEV) antibodies in Swiss blood donors in 2014-2015. Blood Transfus. 21:100–109. 10.2450/2022.0099-22</Citation><ArticleIdList><ArticleId IdType="doi">10.2450/2022.0099-22</ArticleId><ArticleId IdType="pmc">PMC10072989</ArticleId><ArticleId IdType="pubmed">35969138</ArticleId></ArticleIdList></Reference><Reference><Citation>Agudelo, M., Palus M., Keeffe J.R., Bianchini F., Svoboda P., Salát J., Peace A., Gazumyan A., Cipolla M., Kapoor T., et al. . 2021. Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J. Exp. Med. 218:e20210236. 10.1084/jem.20210236</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210236</ArticleId><ArticleId IdType="pmc">PMC8040517</ArticleId><ArticleId IdType="pubmed">33831141</ArticleId></ArticleIdList></Reference><Reference><Citation>Alotaibi, F., Alharbi N.K., Rosen L.B., Asiri A.Y., Assiri A.M., Balkhy H.H., Al Jeraisy M., Mandourah Y., AlJohani S., Al Harbi S., et al. . 2023. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. Influenza Other Respir. Viruses. 17:e13116. 10.1111/irv.13116</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13116</ArticleId><ArticleId IdType="pmc">PMC10028524</ArticleId><ArticleId IdType="pubmed">36960162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Gervais A., Le Voyer T., Philippot Q., Cobat A., Rosain J., Jouanguy E., Abel L., Zhang S.-Y., Zhang Q., et al. . 2024a. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunol. Rev. 322:98–112. 10.1111/imr.13304</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13304</ArticleId><ArticleId IdType="pmc">PMC10950543</ArticleId><ArticleId IdType="pubmed">38193358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Gervais A., Le Voyer T., Rosain J., Philippot Q., Manry J., Michailidis E., Hoffmann H.H., Eto S., Garcia-Prat M., et al. . 2021a. Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths. Sci. Immunol. 6:eabl4340. 10.1126/sciimmunol.abl4340</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Gervais A., Taniguchi M., Saare L., Särekannu K., Le Voyer T., Philippot Q., Rosain J., Bizien L., Asano T., et al. . 2024b. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children. J. Exp. Med. 221:e20231353. 10.1084/jem.20231353</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20231353</ArticleId><ArticleId IdType="pmc">PMC10771097</ArticleId><ArticleId IdType="pubmed">38175961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Orlova E., Sozaeva L., Lévy R., James A., Schmitt M.M., Ochoa S., Kareva M., Rodina Y., Gervais A., et al. . 2021b. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218:e20210554. 10.1084/jem.20210554</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210554</ArticleId><ArticleId IdType="pmc">PMC8077172</ArticleId><ArticleId IdType="pubmed">33890986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Béziat V., et al. . 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eabd4585. 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Vazquez S.E., Liu J., Laurie M.T., Wang C.Y., Gervais A., Le Voyer T., Bizien L., Zamecnik C., Philippot Q., et al. . 2023. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci. Immunol. 8:eabp8966. 10.1126/sciimmunol.abp8966</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abp8966</ArticleId><ArticleId IdType="pmc">PMC9210448</ArticleId><ArticleId IdType="pubmed">35857576</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck, C., Desprès P., Paulous S., Vanhomwegen J., Lowenski S., Nowotny N., Durand B., Garnier A., Blaise-Boisseau S., Guitton E., et al. . 2015. A high-performance multiplex immunoassay for serodiagnosis of flavivirus-associated neurological diseases in horses. Biomed. Res. Int. 2015:678084. 10.1155/2015/678084</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/678084</ArticleId><ArticleId IdType="pmc">PMC4589573</ArticleId><ArticleId IdType="pubmed">26457301</ArticleId></ArticleIdList></Reference><Reference><Citation>Best, S.M., Morris K.L., Shannon J.G., Robertson S.J., Mitzel D.N., Park G.S., Boer E., Wolfinbarger J.B., and Bloom M.E.. 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol. 79:12828–12839. 10.1128/JVI.79.20.12828-12839.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.20.12828-12839.2005</ArticleId><ArticleId IdType="pmc">PMC1235813</ArticleId><ArticleId IdType="pubmed">16188985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bílý, T., Palus M., Eyer L., Elsterová J., Vancová M., and Růžek D.. 2015. Electron tomography analysis of tick-borne encephalitis virus infection in human neurons. Sci. Rep. 5:10745. 10.1038/srep10745</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10745</ArticleId><ArticleId IdType="pmc">PMC4466586</ArticleId><ArticleId IdType="pubmed">26073783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogovic, P., Lotric-Furlan S., and Strle F.. 2010. What tick-borne encephalitis may look like: Clinical signs and symptoms. Trav. Med. Infect. Dis. 8:246–250. 10.1016/j.tmaid.2010.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2010.05.011</ArticleId><ArticleId IdType="pubmed">20970727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogovic, P., and Strle F.. 2015. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J. Clin. Cases. 3:430–441. 10.12998/wjcc.v3.i5.430</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v3.i5.430</ArticleId><ArticleId IdType="pmc">PMC4419106</ArticleId><ArticleId IdType="pubmed">25984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, S.E., Feng A., Meng W., Apostolidis S.A., Mack E., Artandi M., Barman L., Bennett K., Chakraborty S., Chang I., et al. . 2021. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12:5417. 10.1038/s41467-021-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobler, G. 2010. Zoonotic tick-borne flaviviruses. Vet. Microbiol. 140:221–228. 10.1016/j.vetmic.2009.08.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2009.08.024</ArticleId><ArticleId IdType="pubmed">19765917</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumpis, U., Crook D., and Oksi J.. 1999. Tick-borne encephalitis. Clin. Infect. Dis. 28:882–890. 10.1086/515195</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/515195</ArticleId><ArticleId IdType="pubmed">10825054</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz, M., Gadoth A., Shepshelovich D., Shasha D., Rudoler N., and Paran Y.. 2022. Systematic review and meta-analysis of foodborne tick-borne encephalitis, Europe, 1980-2021. Emerg. Infect. Dis. 28:1945–1954. 10.3201/eid2810.220498</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2810.220498</ArticleId><ArticleId IdType="pmc">PMC9514354</ArticleId><ArticleId IdType="pubmed">36149234</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais, A., Le Floc’h C., Le Voyer T., Bizien L., Bohlen J., Celmeli F., Al-Qureshah F., Masson C., Rosain J., Chbihi M., et al. . 2024. A sensitive assay for measuring whole-blood responses to type I IFNsA sensitive assay for measuring whole-blood responses to type I IFNs. Proc. Natl. Acad. Sci. USA. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">39312669</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais, A., Rovida F., Avanzini M.A., Croce S., Marchal A., Lin S.C., Ferrari A., Thorball C.W., Constant O., Le Voyer T., et al. . 2023. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. J. Exp. Med. 220:e20230661. 10.1084/jem.20230661</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20230661</ArticleId><ArticleId IdType="pmc">PMC10287549</ArticleId><ArticleId IdType="pubmed">37347462</ArticleId></ArticleIdList></Reference><Reference><Citation>Goonawardane, N., Upstone L., Harris M., and Jones I.M.. 2022. Identification of host factors differentially induced by clinically diverse strains of tick-borne encephalitis virus. J. Virol. 96:e0081822. 10.1128/jvi.00818-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00818-22</ArticleId><ArticleId IdType="pmc">PMC9517736</ArticleId><ArticleId IdType="pubmed">36098513</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen, K., Kuratli R., Vasou A., Huber M., Hughes D.J., and Hale B.G.. 2024. Highly-sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies. bioRxiv. 10.1101/2024.06.18.599537 (Preprint posted June 22, 2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.06.18.599537</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson, R., Svenungsson B., Forsgren M., Gardulf A., and Granström M.. 1992. Two-year survey of the incidence of Lyme borreliosis and tick-borne encephalitis in a high-risk population in Sweden. Eur. J. Clin. Microbiol. Infect. Dis. 11:894–900. 10.1007/BF01962369</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01962369</ArticleId><ArticleId IdType="pubmed">1486884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale, B.G. 2023. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. Eur. J. Immunol. 53:e2250164. 10.1002/eji.202250164</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202250164</ArticleId><ArticleId IdType="pubmed">37027328</ArticleId></ArticleIdList></Reference><Reference><Citation>Haviernik, J., Eyer L., Yoshii K., Kobayashi S., Cerny J., Nougairède A., Driouich J.-S., Volf J., Palus M., de Lamballerie X., et al. . 2021. Development and characterization of recombinant tick-borne encephalitis virus expressing mCherry reporter protein: A new tool for high-throughput screening of antiviral compounds, and neutralizing antibody assays. Antivir. Res. 185:104968. 10.1016/j.antiviral.2020.104968</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104968</ArticleId><ArticleId IdType="pubmed">33157129</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz, F.X., Stiasny K., Holzmann H., Kundi M., Sixl W., Wenk M., Kainz W., Essl A., and Kunz C.. 2015. Emergence of tick-borne encephalitis in new endemic areas in Austria: 42 years of surveillance. Euro Surveill. 20:9–16. 10.2807/1560-7917.ES2015.20.13.21077</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2015.20.13.21077</ArticleId><ArticleId IdType="pubmed">25860391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignatieva, E.V., Igoshin A.V., and Yudin N.S.. 2017. A database of human genes and a gene network involved in response to tick-borne encephalitis virus infection. BMC Evol. Biol. 17:259. 10.1186/s12862-017-1107-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12862-017-1107-8</ArticleId><ArticleId IdType="pmc">PMC5751789</ArticleId><ArticleId IdType="pubmed">29297316</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgačevski, J., and Potokar M.. 2023. Immune functions of astrocytes in viral neuroinfections. Int. J. Mol. Sci. 24:3514. 10.3390/ijms24043514</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043514</ArticleId><ArticleId IdType="pmc">PMC9960577</ArticleId><ArticleId IdType="pubmed">36834929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser, R. 1999. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: A prospective study of 656 patients. Brain. 122:2067–2078. 10.1093/brain/122.11.2067</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.11.2067</ArticleId><ArticleId IdType="pubmed">10545392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser, R. 2008. Tick-borne encephalitis. Infect. Dis. Clin. North Am. 22:561–575. 10.1016/j.idc.2008.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2008.03.013</ArticleId><ArticleId IdType="pubmed">18755391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser, R. 2012. Tick-borne encephalitis: Clinical findings and prognosis in adults. Wien. Med. Wochenschr. 162:239–243. 10.1007/s10354-012-0105-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10354-012-0105-0</ArticleId><ArticleId IdType="pubmed">22695809</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Voyer, T., Parent A.V., Liu X., Cederholm A., Gervais A., Rosain J., Nguyen T., Perez Lorenzo M., Rackaityte E., Rinchai D., et al. . 2023. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature. 623:803–813. 10.1038/s41586-023-06717-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06717-x</ArticleId><ArticleId IdType="pmc">PMC10665196</ArticleId><ArticleId IdType="pubmed">37938781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist, L., and Vapalahti O.. 2008. Tick-borne encephalitis. Lancet. 371:1861–1871. 10.1016/S0140-6736(08)60800-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)60800-4</ArticleId><ArticleId IdType="pubmed">18514730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindqvist, R., Upadhyay A., and Överby A.K.. 2018. Tick-borne flaviviruses and the type I interferon response. Viruses. 10:340. 10.3390/v10070340</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10070340</ArticleId><ArticleId IdType="pmc">PMC6071234</ArticleId><ArticleId IdType="pubmed">29933625</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansfield, K.L., Johnson N., Phipps L.P., Stephenson J.R., Fooks A.R., and Solomon T.. 2009. Tick-borne encephalitis virus—a review of an emerging zoonosis. J. Gen. Virol. 90:1781–1794. 10.1099/vir.0.011437-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.011437-0</ArticleId><ArticleId IdType="pubmed">19420159</ArticleId></ArticleIdList></Reference><Reference><Citation>Palus, M., Bílý T., Elsterová J., Langhansová H., Salát J., Vancová M., and Růžek D.. 2014. Infection and injury of human astrocytes by tick-borne encephalitis virus. J. Gen. Virol. 95:2411–2426. 10.1099/vir.0.068411-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.068411-0</ArticleId><ArticleId IdType="pubmed">25000960</ArticleId></ArticleIdList></Reference><Reference><Citation>Parfut, A., Laugel E., Baer S., Gonzalez G., Hansmann Y., Wendling M.J., Fafi-Kremer S., and Velay A.. 2023. Tick-borne encephalitis in pediatrics: An often overlooked diagnosis. Infect. Dis. Now. 53:104645. 10.1016/j.idnow.2023.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2023.01.005</ArticleId><ArticleId IdType="pubmed">36642097</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz, A., Erber W., and Schmitt H.-J.. 2023. Vaccine uptake in 20 countries in Europe 2020: Focus on tick-borne encephalitis (TBE). Ticks Tick Borne Dis. 14:102059. 10.1016/j.ttbdis.2022.102059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ttbdis.2022.102059</ArticleId><ArticleId IdType="pubmed">36410164</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokorna Formanova, P., Palus M., Salat J., Hönig V., Stefanik M., Svoboda P., and Ruzek D.. 2019. Changes in cytokine and chemokine profiles in mouse serum and brain, and in human neural cells, upon tick-borne encephalitis virus infection. J. Neuroinflammation. 16:205. 10.1186/s12974-019-1596-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1596-z</ArticleId><ArticleId IdType="pmc">PMC6839073</ArticleId><ArticleId IdType="pubmed">31699097</ArticleId></ArticleIdList></Reference><Reference><Citation>Potokar, M., Korva M., Jorgačevski J., Avšič-Županc T., and Zorec R.. 2014. Tick-borne encephalitis virus infects rat astrocytes but does not affect their viability. PLoS One. 9:e86219. 10.1371/journal.pone.0086219</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086219</ArticleId><ArticleId IdType="pmc">PMC3896472</ArticleId><ArticleId IdType="pubmed">24465969</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel, A., Picard C., Lorrot M., Pons C., Chrabieh M., Lorenzo L., Mamani-Matsuda M., Jouanguy E., Gendrel D., and Casanova J.-L.. 2008. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180:647–654. 10.4049/jimmunol.180.1.647</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.1.647</ArticleId><ArticleId IdType="pubmed">18097067</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel, A., Bastard P., Bustamante J., and Casanova J.L.. 2022. Human autoantibodies underlying infectious diseases. J. Exp. Med. 219:e20211387. 10.1084/jem.20211387</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211387</ArticleId><ArticleId IdType="pmc">PMC8952682</ArticleId><ArticleId IdType="pubmed">35319722</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzišauskienė, D., Urbonienė J., Kaubrys G., Andruškevičius S., Jatužis D., Matulytė E., and Žvirblytė-Skrebutienė K.. 2020. The epidemiology, clinical presentation, and predictors of severe tick-borne encephalitis in Lithuania, a highly endemic country: A retrospective study of 1040 patients. PLoS One. 15:e0241587. 10.1371/journal.pone.0241587</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241587</ArticleId><ArticleId IdType="pmc">PMC7676731</ArticleId><ArticleId IdType="pubmed">33211708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzek, D., Avšič Županc T., Borde J., Chrdle A., Eyer L., Karganova G., Kholodilov I., Knap N., Kozlovskaya L., Matveev A., et al. . 2019. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antivir. Res. 164:23–51. 10.1016/j.antiviral.2019.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.01.014</ArticleId><ArticleId IdType="pubmed">30710567</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins, J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., and Rice C.M.. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 472:481–485. 10.1038/nature09907</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09907</ArticleId><ArticleId IdType="pmc">PMC3409588</ArticleId><ArticleId IdType="pubmed">21478870</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze, D., Dollenmaier G., Rohner A., Guidi T., and Cassinotti P.. 2007. Benefit of detecting tick-borne encephalitis viremia in the first phase of illness. J. Clin. Virol. 38:172–175. 10.1016/j.jcv.2006.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2006.11.008</ArticleId><ArticleId IdType="pubmed">17204453</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligman, S.J. 2014. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 32:5769–5775. 10.1016/j.vaccine.2014.08.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.051</ArticleId><ArticleId IdType="pubmed">25192973</ArticleId></ArticleIdList></Reference><Reference><Citation>Septfons, A., Emma R., Benezet L., Velay A., Zilliox L., Baldinger L., Gonzalez G., Figoni J., de Valk H., Deffontaines G., et al. . 2023. Seroprevalence for Borrelia burgdorferi sensu lato and tick-borne encephalitis virus antibodies and associated risk factors among forestry workers in northern France, 2019 to 2020. Euro Surveill. 28:2200961. 10.2807/1560-7917.ES.2023.28.32.2200961</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.32.2200961</ArticleId><ArticleId IdType="pmc">PMC10416575</ArticleId><ArticleId IdType="pubmed">37561054</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw, E.R., Rosen L.B., Cheng A., Dobbs K., Delmonte O.M., Ferré E.M.N., Schmitt M.M., Imberti L., Quaresima V., Lionakis M.S., et al. . 2022. Temporal dynamics of anti-type 1 interferon autoantibodies in patients with coronavirus disease 2019. Clin. Infect. Dis. 75:e1192–e1194. 10.1093/cid/ciab1002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab1002</ArticleId><ArticleId IdType="pmc">PMC8689695</ArticleId><ArticleId IdType="pubmed">34875033</ArticleId></ArticleIdList></Reference><Reference><Citation>Smithburn, K.C., Hughes T.P., Burke A.W., and Paul J.H.. 1940. A neurotropic virus isolated from the blood of a native of Uganda. Am. J. Trop. Med. s1-20:471–492. 10.4269/ajtmh.1940.s1-20.471</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.1940.s1-20.471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonja, F., Nina K.M., Irene A.A., Kevin G., Roger K., Marie L., Christian W.T., Enos B., Paraskevas F., Karoline L., et al. . 2024. Longitudinal analysis over decades reveals the development and immune implications of type I interferon autoantibodies in an aging population. medRxiv. 10.1101/2024.02.27.24303363123456 (Preprint posted March 06, 2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.27.24303363123456</ArticleId></ArticleIdList></Reference><Reference><Citation>Steels, S., Van Elslande J., De Munter P., Bossuyt X., Imbrechts M., Dillaerts D., Meyts I., Geukens N., Wauters E., Vermeersch P., et al. . 2022. Transient increase of pre-existing anti-IFN-α2 antibodies induced by SARS-CoV-2 infection. J. Clin. Immunol. 42:742–745. 10.1007/s10875-022-01235-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01235-3</ArticleId><ArticleId IdType="pmc">PMC8926884</ArticleId><ArticleId IdType="pubmed">35296990</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiasny, K., Aberle J.H., Chmelik V., Karrer U., Holzmann H., and Heinz F.X.. 2012. Quantitative determination of IgM antibodies reduces the pitfalls in the serodiagnosis of tick-borne encephalitis. J. Clin. Virol. 54:115–120. 10.1016/j.jcv.2012.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.02.016</ArticleId><ArticleId IdType="pubmed">22421535</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone, E.T., and Pinto A.K.. 2023. T cells in tick-borne flavivirus encephalitis: A review of current paradigms in protection and disease pathology. Viruses. 15:958. 10.3390/v15040958</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040958</ArticleId><ArticleId IdType="pmc">PMC10146733</ArticleId><ArticleId IdType="pubmed">37112938</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, H.C., Jing H., Zhang Y., and Casanova J.L.. 2023. Interfering with interferons: A critical mechanism for critical COVID-19 pneumonia. Annu. Rev. Immunol. 41:561–585. 10.1146/annurev-immunol-101921-050835</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-101921-050835</ArticleId><ArticleId IdType="pubmed">37126418</ArticleId></ArticleIdList></Reference><Reference><Citation>Werme, K., Wigerius M., and Johansson M.. 2008. Tick-borne encephalitis virus NS5 associates with membrane protein scribble and impairs interferon-stimulated JAK-STAT signalling. Cell. Microbiol. 10:696–712. 10.1111/j.1462-5822.2007.01076.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2007.01076.x</ArticleId><ArticleId IdType="pubmed">18042258</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii, K. 2019. Epidemiology and pathological mechanisms of tick-borne encephalitis. J. Vet. Med. Sci. 81:343–347. 10.1292/jvms.18-0373</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.18-0373</ArticleId><ArticleId IdType="pmc">PMC6451894</ArticleId><ArticleId IdType="pubmed">30674746</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavadska, D., Anca I., André F., Bakir M., Chlibek R., Cižman M., Ivaskeviciene I., Mangarov A., Mészner Z., Pokorn M., et al. . 2013. Recommendations for tick-borne encephalitis vaccination from the central European vaccination awareness group (CEVAG). Hum. Vaccin. Immunother. 9:362–374. 10.4161/hv.22766</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.22766</ArticleId><ArticleId IdType="pmc">PMC3859759</ArticleId><ArticleId IdType="pubmed">23291941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q., Pizzorno A., Miorin L., Bastard P., Gervais A., Le Voyer T., Bizien L., Manry J., Rosain J., Philippot Q., et al. . 2022. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med. 219:e20220514. 10.1084/jem.20220514</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220514</ArticleId><ArticleId IdType="pmc">PMC9485705</ArticleId><ArticleId IdType="pubmed">36112363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>